Rezolute Inc. (RZLT)
NASDAQ: RZLT
· Real-Time Price · USD
9.10
-0.09 (-0.98%)
At close: Oct 03, 2025, 3:59 PM
9.11
0.11%
After-hours: Oct 03, 2025, 06:45 PM EDT
-0.98% (1D)
| Bid | 9 |
| Market Cap | 826.38M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -74.41M |
| EPS (ttm) | -0.98 |
| PE Ratio (ttm) | -9.29 |
| Forward PE | -8.84 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 9.11 |
| Volume | 1,297,285 |
| Avg. Volume (20D) | 1,093,522 |
| Open | 9.30 |
| Previous Close | 9.19 |
| Day's Range | 9.01 - 9.44 |
| 52-Week Range | 2.21 - 9.72 |
| Beta | 0.05 |
| Ex-Dividend Date | n/a |
About RZLT
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol RZLT
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for RZLT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts5 months ago
+27.65%
Rezolute shares are trading higher after the compa...
Unlock content with
Pro Subscription
2 weeks ago · seekingalpha.com
Rezolute: FDA Pivotal Trial Alignment Change Further Bolsters ErsodetugRezolute is advancing ersodetug in two phase 3 trials for hyperinsulinism: sunRIZE for congenital HI and upLIFT for tumor HI, respectively. RZLT secured FDA alignment for the upLIFT pivotal trial, all...
